SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The national debt has increased every year for the past ten years, and interest expenses have remained fairly stable due to low interest rates and the perceived low risk of U.S. government default, according to the U.S. Treasury Fiscal Data. This coin is a parody coin about the debt crises in the US and to highlight various aspects about this crises in a humouros way to the people on solana. $USNDC

UnitedStates National Debt Coin

UnitedStates National Debt Coin ($USNDC.X) is trending as community members highlight growing buzz and meme activity, particularly within the Phantom wallet ecosystem. The coin is generating attention as a potential "sleeper gem" within the Solana network, with some users noting increased on-chain transfer notifications and rising volume.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB.X is trending as the community anticipates an upcoming halving event, drawing comparisons to Bitcoin due to its capped supply. Discussions highlight its potential within the ICP ecosystem, with some users pointing to its outperformance relative to ICP and its role in generating revenue. Speculation is increasing around its potential for significant gains, with some community members actively adding to their positions.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending as the community discusses its potential use by SWIFT for stablecoin payment tests, sparking bullish sentiment. The conversations include speculation about its price potential and comparisons to other cryptocurrencies like XRP. Some users are also discussing related tokens and projects within the Ethereum ecosystem.

Ares Acquisition Corp. II is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on March 15, 2021 and is headquartered in New York, NY.

Kodiak AI Inc.

Kodiak AI Inc. - Ordinary Shares - Class A

Kodiak AI (KDK) is trending due to its focus on autonomous trucking solutions, with community members highlighting partnerships and potential for growth in a $4T market. Discussions center on the recent merger vote and the involvement of institutional investors like Cathie Wood and Soros Fund Management. Some are watching for a potential price surge post-merger, while others express concerns about market conditions and potential dilution.

"What's Updog?" is a Community Led token.

UpDog

UpDog is gaining traction as community members highlight its long-term presence on the Solana network and growing holder base. Many are drawn to its strong community and are actively using Jupiter to swap SOL for UPDOG.X, while others playfully ask, "What's UpDog?"

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending amid speculation of a potential acquisition, particularly by Palo Alto Networks, although this remains unconfirmed and recent reports suggest otherwise. Community discussion includes debate over valuation, with some seeing it as undervalued compared to competitors like CrowdStrike, and others pointing to insider selling and lackluster historical performance. Despite the uncertainty, some investors are accumulating shares, betting on the company's long-term vision in AI-powered cybersecurity.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies ($BIAF) is trending due to recent case studies highlighting the effectiveness of its CyPath Lung test for early lung cancer detection, which could reduce unnecessary biopsies. The community is discussing the stock's potential for a significant run, citing its low float and possible buyout interest from major pharmaceutical companies. Some traders are wary of dilution, while others are focused on the company's long-term investment potential due to its technology addressing a critical need in cancer diagnostics.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind is trending as investors discuss the potential FDA approval of Afrezza for pediatric use and the recent positive results from United Therapeutics' TETON-2 trial, which could significantly boost Tyvaso DPI royalties; community members are also weighing the potential impact of the SC Pharma acquisition, and a second drug collaboration with United Therapeutics. Bullish sentiment is building around key catalysts that could drive revenue growth and profitability, though some express concern over leadership and execution. The community is closely watching for analyst upgrades and potential M&A activity, with a few members saying they think there is a strong likelihood of a buyout in the future.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

ARCT is trending due to upcoming data readouts for its cystic fibrosis (CF) and ornithine transcarbamylase deficiency (OTC) programs, with the community actively discussing potential trial results and market impact. Recent insider buying and analyst target price adjustments are also fueling interest.  Some traders are pointing to option activity and technical indicators as potential signals for an upward move.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending amid discussions about a potential bottom after a recent drop, with investors analyzing level 2 market data for signals of a reversal. Community members are debating whether the stock is undervalued, highlighting its growth potential and debt-free balance sheet, while some compare it unfavorably to competitors like Chipotle. The stock's recent performance and expansion plans are key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock?

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -26.87% and -32.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Latest Ratings for EYPT
 DateFirmActionFromTo Nov 2021HC Wainwright & Co.MaintainsBuy May 2021HC Wainwright & Co.MaintainsBuy Jan 2021Cantor FitzgeraldInitiates Coverage OnOverweight
 View More...

Shares of 4D Molecular Therapeutics Inc. (FDMT) plummeted over 35% to $17.30 by Wednesday afternoon, marking it as the top loser among U.S. stocks. Surprisingly, retail traders remain highly bullish on the stock, with Stocktwits sentiment extremely bullish (85/100) amid extremely high message volumes (95/100).<figure class="image"><img style="aspect-ratio:1308/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_Sentiment_Meter_On_Jul_17_5f2f85024d.png" alt="FDMT Stocktwits Sentiment Meter On Jul 17" width="1308" height="308"><figcaption>FDMT Stocktwits Sentiment Meter On Jul 17</figcaption></figure>Initially, FDMT shares climbed following the release of encouraging mid-stage clinical study results for its 4D-150 gene therapy, aimed at treating wet age-related macular degeneration (wAMD), a chronic eye disorder that leads to blurred vision or blind spots in central vision.However, the broader market turned its focus to various downside risks, including safety concerns raised by RBC Capital. While the firm maintains 4D-150 is "best in class," it flagged a "safety blip" – one case of inflammation in a patient with a history of syphilis, Investing.com <a href="https://in.investing.com/news/stock-market-news/4d-molecular-therapeutics-tumbles-following-midstage-clinical-study-results-432SI-4316187">reported</a>. BMO Capital lowering the price target further may have added to the pressure.Despite the sell-off, retail investors on Stocktwits seem to view Wednesday’s crash as a buying opportunity. One user noted that 4D’s peers, Ocular Therapeutix Inc. (OCUL), Adverum Biotechnologies Inc (ADVM) and EyePoint Pharmaceuticals Inc. (EYPT), “are taking it on the chin today.”“Obviously, Nasdaq taking it hard today as well. &nbsp;Perhaps, just a general opinion of overvaluation and market fatigue? &nbsp;Very odd stock movement to me, I do expect it will reverse soon,” said Stocktwits user ‘<a href="https://stocktwits.com/ehschunk/message/579821570">ehschunk</a>’.<figure class="image"><img style="aspect-ratio:1318/454;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_stocktwits_comment_Jul_17_88b7f49b68.png" alt="Stocktwits user ehschunk's post on FDMT stream" width="1318" height="454"><figcaption>Stocktwits user ehschunk's post on FDMT stream</figcaption></figure>The overall market sentiment didn’t help, as U.S. stocks pulled back from their all-time highs on Wednesday, impacted by falling chip and tech stocks, though the Dow Jones managed its sixth consecutive day of gains.FDMT shares are down over 19% year-to-date, contrasting with OCUL’s impressive 65% rise. EYPT has had an even tougher year, losing 57% so far, while ADVM has lost only 0.18%.However, FDMT’s consistent performance in beating EPS estimates for the past four quarters provides some relief and hope for a rebound among its retail investors.

Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics

Wall Street’s Top Loser Today Remains In Retail’s Good Books

Equity

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics on promising clinical study results

Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.
read more...

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O...

EyePoint Pharmaceuticals (EYPT, $20.27) RSI Indicator left the oversold zone on April 01, 2024

This is a signal that EYPT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

EyePoint Pharmaceuticals (EYPT, $20.27) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that EYPT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Pharmaceuticals Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

EYPT
EyePoint Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EYPT News

EYPT EyePoint Pharmaceuticals Inc